Lazertinib European Commercialization Milestone Achieved, $30M Payment Received
- Milestone achieved due to European commercialization start of lazertinib+amivantamab combination therapy licensed to Janssen
- Expected milestone payment of $30,000,000 (approx. KRW 44.9 billion, 2.05% of consolidated revenue)
- Invoice date: 2026-05-14, payment expected within 60 days
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: Other Management Matters (Voluntary Disclosure)
- Company: Yuhan (000100)
- Submission: Yuhan Corporation
- Receipt: 05-14-2026
- Under KRX KOSPI Market Division